Pyridorin in type 2 diabetic nephropathy.
Pyridoxamine dihydrochloride (Pyridorin, NephroGenex) inhibits formation of advanced glycation end products and scavenges reactive oxygen species and toxic carbonyls, but whether these actions translate into renoprotective effects is unknown. In this double-blind, randomized, placebo-controlled trial, we randomly assigned 317 patients with proteinuric type 2 diabetic nephropathy to twice-daily placebo; Pyridorin, 150 mg twice daily; or Pyridorin, 300 mg twice daily, for 52 weeks. At baseline, the mean age ± SD was 63.9±9.5 years, and the mean duration of diabetes was 17.6±8.5 years; the mean serum creatinine level was 2.2±0.6 mg/dl, and the mean protein-to-creatinine ratio was 2973±1932 mg/g. Regarding the primary end point, a statistically significant change in serum creatinine from baseline to 52 weeks was not evident in either Pyridorin group compared with placebo. However, analysis of covariance suggested that the magnitude of the treatment effect differed by baseline renal function. Among patients in the lowest tertile of baseline serum creatinine concentration, treatment with Pyridorin associated with a lower average change in serum creatinine concentration at 52 weeks (0.28, 0.07, and 0.14 mg/dl for placebo, Pyridorin 150 mg, and Pyridorin 300 mg, respectively; P=0.05 for either Pyridorin dose versus placebo); there was no evidence of a significant treatment effect in the middle or upper tertiles. In conclusion, this trial failed to detect an effect of Pyridorin on the progression of serum creatinine at 1 year, although it suggests that patients with less renal impairment might benefit.
Rush University Medical Center, Chicago, Illinois, USA.
Edmund J
EJ
Lewis
Tom
T
Greene
Samuel
S
Spitalewiz
Samuel
S
Blumenthal
Tomas
T
Berl
Lawrence G
LG
Hunsicker
Marc A
MA
Pohl
Richard D
RD
Rohde
Itamar
I
Raz
Yair
Y
Yerushalmy
Yoram
Y
Yagil
Tommy
T
Herskovits
Robert C
RC
Atkins
Anne T
AT
Reutens
David K
DK
Packham
Julia B
JB
Lewis
D000368:Aged; D003404:Creatinine / Q000097:blood; D055316:Cystatin C / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003928:Diabetic Nephropathies / Q000097:blood / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D008297:Male; D008875:Middle Aged; D011507:Proteinuria / Q000652:urine; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives; D011733:Pyridoxamine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D055316:Cystatin C; D011732:Pyridoxal Phosphate; D011733:Pyridoxamine; D003404:Creatinine; C570561:pyridoxamine dihydrochloride